Citi raised the firm’s price target on Crispr Therapeutics to $89 from $88 and keeps a Buy rating on the shares. The analyst updated the company’s model to reflect the reported Q4 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
- Are Investors Vastly Underestimating CRISPR Therapeutics Stock (NASDAQ:CRSP)?
- Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Crispr Therapeutics proposes to elect Christian Rommel to board of directors
